サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1514005

急性冠症候群の世界市場

Acute Coronary Syndrome

出版日
ページ情報
英文 182 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
急性冠症候群の世界市場
出版日: 2024年07月17日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 182 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

急性冠症候群の世界市場は2030年までに176億米ドルに達する見込み

2023年に87億米ドルと推定される急性冠症候群の世界市場は、2030年には176億米ドルに達し、分析期間2023-2030年のCAGRは10.5%で成長すると予測されます。

米国市場は23億米ドル、中国はCAGR16.4%で成長予測

米国の急性冠症候群市場は2023年に23億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに45億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは16.4%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ4.5%と10.3%と予測されています。欧州では、ドイツがCAGR約6.4％で成長すると予測されています。

急性冠症候群-主要動向と促進要因

急性冠症候群（ACS）は、心筋への血流が突然減少することによって生じる心臓関連の問題のスペクトルを包含する重篤な状態です。この領域には、不安定狭心症、非ST上昇型心筋梗塞（NSTEMI）、ST上昇型心筋梗塞（STEMI）が含まれます。ACSの主な原因は冠動脈内のアテローム性動脈硬化斑の破裂または浸食であり、血栓（血の塊）が形成されて動脈の一部または全部が閉塞します。この閉塞は心筋への酸素供給を低下させ、虚血を引き起こし、未治療の場合は心筋梗塞（心臓発作）につながります。患者は通常、胸痛や不快感などの症状を呈し、その症状は腕、首、顎、背中にまで広がることがあり、息切れ、発汗、吐き気、めまいなどを伴うこともあります。早期かつ正確な診断が重要であり、一般的には臨床評価、心電図（ECG）、トロポニンなどの心臓バイオマーカーの血液検査、心エコー検査や冠動脈造影などの画像検査を組み合わせることによって達成されます。

ACSの治療戦略は、血流を速やかに回復させ、心筋の損傷を最小限に抑え、さらなる合併症を予防することを目的とします。薬理学的介入としては，抗血小板薬（アスピリンやP2Y12阻害薬など），抗凝固薬（ヘパリンなど），β遮断薬，硝酸薬，スタチンなどがあり，これらはまとめてプラークの安定化，血栓形成の抑制，症状の管理，さらなる心血管イベントの予防に役立ちます。重度の動脈閉塞や胸痛が続く患者には、経皮的冠動脈インターベンション（PCI）や冠動脈バイパス術（CABG）などのインターベンション治療が行われます。PCIはしばしば薬剤溶出ステントの留置を伴うが，再狭窄（動脈の再狭窄）を減少させる効果があるため，ACS管理の要となっています。このようなインターベンション手技の進歩は、新しい抗血小板薬や抗凝固薬の開発とともに、ACS患者の生存率と転帰を著しく改善しました。急性期治療後の管理には、生活習慣の改善、心臓リハビリテーション、イベント再発リスクを軽減するための長期服薬順守などが含まれます。

ACS市場の成長はいくつかの要因によってもたらされます。第一に、心血管系疾患の有病率の増加が主要な促進要因であり、その主な原因は、人口の高齢化と、肥満、運動不足、食生活の乱れ、喫煙、糖尿病や高血圧の罹患率の上昇といった生活習慣に関連した危険因子です。第二に、診断技術の進歩により、ACSの早期かつ正確な発見が可能になっています。高感度の心臓バイオマーカーと心臓MRIやCT血管造影のような高度な画像診断技術により、タイムリーで正確な診断が可能となり、これは効果的な介入に不可欠です。第三に、新規治療薬や高度なインターベンション手技の継続的な開拓により、治療の選択肢が拡大し、患者の転帰が改善され、市場の成長が促進されています。さらに、心血管系の健康に対する認識と教育が高まっており、より多くの人が症状の早期発現時に医療機関を受診するようになっているため、ACS関連のヘルスケアサービスの需要が増加しています。心血管治療のインフラと研究の強化に重点を置いた政府のイニシアチブと資金援助も市場を強化しています。最後に、遠隔医療とデジタルヘルスソリューションの統合は、患者のモニタリングとフォローアップケアを強化し、ACSのより良い管理を可能にし、市場全体の拡大に寄与しています。こうしたデジタルの進歩により、患者の遠隔モニタリング、タイムリーな医療介入、治療レジメンのアドヒアランス向上が可能になり、ACS市場の成長をさらに促進しています。

調査対象企業の例（全62件）

  • Amgen, Inc.
  • Astellas Pharma, Inc.
  • AstraZeneca PLC
  • Biological E. Ltd.
  • Daiichi Sankyo Co., Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Momenta Pharmaceuticals, Inc.
  • Pfizer, Inc.
  • Recordati SpA
  • The Medicines Company

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP-6355

Global Acute Coronary Syndrome Market to Reach US$17.6 Billion by 2030

The global market for Acute Coronary Syndrome estimated at US$8.7 Billion in the year 2023, is expected to reach US$17.6 Billion by 2030, growing at a CAGR of 10.5% over the analysis period 2023-2030.

The U.S. Market is Estimated at US$2.3 Billion While China is Forecast to Grow at 16.4% CAGR

The Acute Coronary Syndrome market in the U.S. is estimated at US$2.3 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$4.5 Billion by the year 2030 trailing a CAGR of 16.4% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.5% and 10.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.4% CAGR.

Acute Coronary Syndrome - Key Trends and Drivers

Acute Coronary Syndrome (ACS) is a critical condition that encompasses a spectrum of heart-related issues arising from the sudden reduction of blood flow to the heart muscle. This spectrum includes unstable angina, non-ST-elevation myocardial infarction (NSTEMI), and ST-elevation myocardial infarction (STEMI). The primary underlying cause of ACS is the rupture or erosion of atherosclerotic plaques within the coronary arteries, leading to thrombus (blood clot) formation that partially or fully obstructs the artery. This obstruction compromises oxygen delivery to the heart muscle, causing ischemia and, if untreated, can lead to myocardial infarction (heart attack). Patients typically present with symptoms such as chest pain or discomfort, which may radiate to the arm, neck, jaw, or back, as well as shortness of breath, sweating, nausea, and dizziness. Early and accurate diagnosis is crucial and is typically achieved through a combination of clinical evaluation, electrocardiograms (ECGs), blood tests for cardiac biomarkers like troponins, and imaging studies such as echocardiography or coronary angiography.

Treatment strategies for ACS are aimed at quickly restoring blood flow, minimizing heart muscle damage, and preventing further complications. Pharmacological interventions include antiplatelet agents (e.g., aspirin and P2Y12 inhibitors), anticoagulants (e.g., heparin), beta-blockers, nitrates, and statins, which collectively help in stabilizing the plaque, reducing clot formation, managing symptoms, and preventing further cardiovascular events. For patients with severe artery blockage or ongoing chest pain, interventional procedures such as percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) are employed. PCI, which often involves the placement of drug-eluting stents, has become a cornerstone in ACS management due to its efficacy in reducing restenosis (re-narrowing of the artery). Advances in these interventional techniques, along with the development of new antiplatelet and anticoagulant medications, have significantly improved survival rates and outcomes for ACS patients. Post-acute management includes lifestyle modifications, cardiac rehabilitation, and long-term medication adherence to mitigate the risk of recurrent events.

The growth in the ACS market is driven by several factors. Firstly, the increasing prevalence of cardiovascular diseases is a major driver, largely due to aging populations and lifestyle-related risk factors such as obesity, physical inactivity, poor diet, smoking, and the rising incidence of diabetes and hypertension. Secondly, advancements in diagnostic technologies are enabling earlier and more precise detection of ACS. High-sensitivity cardiac biomarkers and advanced imaging techniques like cardiac MRI and CT angiography allow for timely and accurate diagnosis, which is critical for effective intervention. Thirdly, the continuous development of novel therapeutic agents and sophisticated interventional procedures is expanding the arsenal of treatment options, thereby improving patient outcomes and driving market growth. Additionally, there is a growing awareness and education about cardiovascular health, which is encouraging more individuals to seek medical attention at the early onset of symptoms, thus increasing the demand for ACS-related healthcare services. Government initiatives and funding focused on enhancing cardiovascular care infrastructure and research are also bolstering the market. Lastly, the integration of telemedicine and digital health solutions is enhancing patient monitoring and follow-up care, enabling better management of ACS and contributing to overall market expansion. These digital advancements allow for remote patient monitoring, timely medical interventions, and improved adherence to treatment regimens, further driving the growth of the ACS market.

Select Competitors (Total 62 Featured) -

  • Amgen, Inc.
  • Astellas Pharma, Inc.
  • AstraZeneca PLC
  • Biological E. Ltd.
  • Daiichi Sankyo Co., Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Johnson & Johnson
  • Momenta Pharmaceuticals, Inc.
  • Pfizer, Inc.
  • Recordati SpA
  • The Medicines Company

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Acute Coronary Syndrome - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Prevalence of Cardiovascular Diseases Expands Addressable Market Opportunity
    • Aging Population Throws the Spotlight on Growing Incidence of ACS
    • Rising Rates of Obesity and Diabetes Propel Growth in ACS Cases
    • Advances in Diagnostic Technologies Spur Adoption of Early Detection Methods
    • Development of High-Sensitivity Cardiac Biomarkers Strengthens Business Case for Precise Diagnosis
    • Innovations in Imaging Techniques Improve ACS Detection
    • Enhanced Antiplatelet and Anticoagulant Therapies Generate Demand for Advanced Treatment Options
    • Integration of Drug-Eluting Stents in PCI Procedures Drives Adoption of Interventional Treatments
    • Increased Awareness and Education on Heart Health Propel Growth in Preventive Measures
    • Advances in Telemedicine and Digital Health Solutions Aid Better ACS Management
    • Expansion of Cardiac Rehabilitation Programs Drives Demand for Post-Treatment Services
    • Increasing Utilization of Artificial Intelligence in ACS Diagnosis and Treatment
    • Focus on Reducing Hospital Readmission Rates Strengthens Business Case for Effective ACS Management
    • Adoption of Mobile Health Applications for Heart Monitoring Drives Market Growth
    • Expansion of Healthcare Services in Emerging Markets Expands Addressable Market for ACS Solutions
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Acute Coronary Syndrome Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Acute Coronary Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Acute Coronary Syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Acute Coronary Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 5: USA Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 6: USA Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • CANADA
    • TABLE 7: Canada Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 8: Canada Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • JAPAN
    • Acute Coronary Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 9: Japan Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 10: Japan Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • CHINA
    • Acute Coronary Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 11: China Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 12: China Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • EUROPE
    • Acute Coronary Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 13: Europe Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 14: Europe Historic Review for Acute Coronary Syndrome by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 15: Europe 16-Year Perspective for Acute Coronary Syndrome by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • FRANCE
    • Acute Coronary Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 16: France Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 17: France Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • GERMANY
    • Acute Coronary Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 18: Germany Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 19: Germany Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • ITALY
    • TABLE 20: Italy Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Italy Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • UNITED KINGDOM
    • Acute Coronary Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 22: UK Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 23: UK Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • SPAIN
    • TABLE 24: Spain Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 25: Spain Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • RUSSIA
    • TABLE 26: Russia Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Russia Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • REST OF EUROPE
    • TABLE 28: Rest of Europe Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 29: Rest of Europe Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • ASIA-PACIFIC
    • Acute Coronary Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 30: Asia-Pacific Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 31: Asia-Pacific Historic Review for Acute Coronary Syndrome by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 32: Asia-Pacific 16-Year Perspective for Acute Coronary Syndrome by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • AUSTRALIA
    • Acute Coronary Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 33: Australia Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 34: Australia Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • INDIA
    • Acute Coronary Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 35: India Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: India Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • SOUTH KOREA
    • TABLE 37: South Korea Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 38: South Korea Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • REST OF ASIA-PACIFIC
    • TABLE 39: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 40: Rest of Asia-Pacific Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • LATIN AMERICA
    • Acute Coronary Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 41: Latin America Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 42: Latin America Historic Review for Acute Coronary Syndrome by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Latin America 16-Year Perspective for Acute Coronary Syndrome by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 44: Argentina Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Argentina Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • BRAZIL
    • TABLE 46: Brazil Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 47: Brazil Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • MEXICO
    • TABLE 48: Mexico Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 49: Mexico Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • REST OF LATIN AMERICA
    • TABLE 50: Rest of Latin America Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Rest of Latin America Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • MIDDLE EAST
    • Acute Coronary Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 52: Middle East Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 53: Middle East Historic Review for Acute Coronary Syndrome by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 54: Middle East 16-Year Perspective for Acute Coronary Syndrome by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
  • IRAN
    • TABLE 55: Iran Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 56: Iran Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • ISRAEL
    • TABLE 57: Israel Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 58: Israel Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • SAUDI ARABIA
    • TABLE 59: Saudi Arabia Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Saudi Arabia Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • UNITED ARAB EMIRATES
    • TABLE 61: UAE Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 62: UAE Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • REST OF MIDDLE EAST
    • TABLE 63: Rest of Middle East Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 64: Rest of Middle East Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • AFRICA
    • Acute Coronary Syndrome Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 65: Africa Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Africa Historic Review for Acute Coronary Syndrome by Segment - Acute Coronary Syndrome Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR

IV. COMPETITION